IN2014KN02752A - - Google Patents

Info

Publication number
IN2014KN02752A
IN2014KN02752A IN2752KON2014A IN2014KN02752A IN 2014KN02752 A IN2014KN02752 A IN 2014KN02752A IN 2752KON2014 A IN2752KON2014 A IN 2752KON2014A IN 2014KN02752 A IN2014KN02752 A IN 2014KN02752A
Authority
IN
India
Prior art keywords
cys11
xaa14
xaa15
xaa13
xaa8
Prior art date
Application number
Other languages
English (en)
Inventor
Frank Otto Gombert
Daniel Obrecht
Alexander Lederer
Johann Zimmermann
Christian Oefner
Original Assignee
Polyphor Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polyphor Ag filed Critical Polyphor Ag
Publication of IN2014KN02752A publication Critical patent/IN2014KN02752A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IN2752KON2014 2012-06-06 2012-06-06 IN2014KN02752A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/060766 WO2013182240A1 (en) 2012-06-06 2012-06-06 Beta-hairpin peptidomimetics

Publications (1)

Publication Number Publication Date
IN2014KN02752A true IN2014KN02752A (pt) 2015-05-08

Family

ID=46208596

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2752KON2014 IN2014KN02752A (pt) 2012-06-06 2012-06-06

Country Status (13)

Country Link
US (2) US9617308B2 (pt)
EP (1) EP2859012B1 (pt)
JP (1) JP6047231B2 (pt)
CN (1) CN104603145B (pt)
AU (1) AU2012381808B2 (pt)
CA (1) CA2875733C (pt)
ES (1) ES2647076T3 (pt)
HK (1) HK1207867A1 (pt)
IL (1) IL235946B (pt)
IN (1) IN2014KN02752A (pt)
MX (1) MX355396B (pt)
SG (1) SG11201407837WA (pt)
WO (1) WO2013182240A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104090A1 (en) 2007-02-28 2008-09-04 Polyphor Ag Template-fixed peptidomimetics
IN2014KN02752A (pt) * 2012-06-06 2015-05-08 Polyphor Ag
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
CN106999536B (zh) 2014-09-11 2020-11-27 百时美施贵宝公司 Pd-1/pd-l1及cd80(b7-1)/pd-l1蛋白质/蛋白质相互作用的大环抑制剂
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
AU2017268291B2 (en) 2016-05-19 2022-09-29 Bristol-Myers Squibb Company PET-imaging immunomodulators
CN109922818B (zh) * 2016-09-06 2024-02-20 主线生物科学公司 Cxcr4拮抗剂及使用方法
KR102526034B1 (ko) 2016-11-07 2023-04-25 브리스톨-마이어스 스큅 컴퍼니 면역조정제
WO2018237153A1 (en) 2017-06-23 2018-12-27 Bristol-Myers Squibb Company IMMUNOMODULATORS ACTING AS PD-1 ANTAGONISTS
US11123437B2 (en) 2017-09-05 2021-09-21 Mainline Biosciences, Inc. Selective CXCR4 binding peptide conjugate and methods for making and using the same
WO2019050564A1 (en) * 2017-09-05 2019-03-14 Mainline Biosciences CXCR4 SELECTIVE BINDING CONJUGATE WITH HIGH AFFINITY AND METHOD OF USING THE SAME
EP3692053A1 (en) 2017-10-03 2020-08-12 Bristol-Myers Squibb Company Immunomodulators
JP2023516878A (ja) * 2020-01-26 2023-04-21 メインライン バイオサイエンシーズ(シャンハイ)シーオー.,エルティーディ. 同位体標識された選択的cxcr4結合性ペプチドコンジュゲート並びにその作製方法及び使用方法
KR20230129388A (ko) 2020-11-19 2023-09-08 스펙시스 아게 암 치료를 위한 펩타이드 cxcr4 억제제 및 탁산을 포함하는 약제학적 조합물
WO2022184320A2 (en) 2021-03-03 2022-09-09 Spexis Ag Medical use of cyclic peptides
WO2023285681A1 (en) 2021-07-16 2023-01-19 Spexis Ag Pharmaceutical combinations for treating cancer
WO2023285677A1 (en) 2021-07-16 2023-01-19 Spexis Ag Pharmaceutical combinations for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212288A (en) * 1990-02-20 1993-05-18 Syntex (U.S.A.) Inc. Temporary minimal protection synthesis of serine-containing polypeptides
AU2003232253A1 (en) * 2003-05-02 2004-11-23 Polyphor Ag Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
EP1991562A2 (en) * 2006-02-27 2008-11-19 Technische Universität München Cancer imaging and treatment
WO2008104090A1 (en) * 2007-02-28 2008-09-04 Polyphor Ag Template-fixed peptidomimetics
US8865656B2 (en) * 2009-05-07 2014-10-21 Polyphor Ag Beta-hairpin peptidomimetics having CXCR4 antagonizing activity
US8716242B2 (en) * 2009-12-04 2014-05-06 Polyphor Ag β-hairpin peptidomimetics
AU2012266355B2 (en) * 2011-06-07 2016-06-09 Polyphor Ag Beta - hairpin peptidomimetics as CXC4 antagonists
IN2014KN02752A (pt) * 2012-06-06 2015-05-08 Polyphor Ag

Also Published As

Publication number Publication date
CN104603145B (zh) 2018-05-18
MX2014014840A (es) 2015-02-12
US20170165319A1 (en) 2017-06-15
US10363284B2 (en) 2019-07-30
CN104603145A (zh) 2015-05-06
WO2013182240A1 (en) 2013-12-12
CA2875733A1 (en) 2013-12-12
NZ702470A (en) 2016-12-23
EP2859012A1 (en) 2015-04-15
AU2012381808B2 (en) 2017-04-27
IL235946A0 (en) 2015-01-29
US20150218219A1 (en) 2015-08-06
US9617308B2 (en) 2017-04-11
HK1207867A1 (en) 2016-02-12
ES2647076T3 (es) 2017-12-19
IL235946B (en) 2019-06-30
JP6047231B2 (ja) 2016-12-21
MX355396B (es) 2018-04-18
JP2015521204A (ja) 2015-07-27
SG11201407837WA (en) 2014-12-30
EP2859012B1 (en) 2017-08-09
CA2875733C (en) 2019-09-10
AU2012381808A1 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
IN2014KN02752A (pt)
MX343205B (es) Peptidomiméticos de horquilla beta como antagonistas de cxc4.
MX2009008843A (es) Peptidomimeticos fijados a un patron.
IL273194B2 (en) Methods, compounds and preparations for the treatment of parainfluenza virus in patients with a deficiency in the immune system
NZ602471A (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
NZ709260A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP3190186A3 (en) Expression of mirnas in placental tissue
ES2397889A1 (es) PÉPTIDOS MODULADORES DE PGC-1Alfa.
MX2017012393A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
MX355474B (es) Compuestos de heterociclilo como inhibidores de mek.
MX363050B (es) Composición inmunogénica para modulación del sistema inmune y su uso, metodo de tratamiento y prevención de enfermedades, método para inducir la regeneración celular y procedimiento para la reconducción de la respuesta inmune.
NZ732391A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
JP2017532343A5 (pt)
GR1007832B (el) Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
GB2546224A (en) Method and composition for producing enhanced anti-inflammatory/ anti-catabolic and regenerative agents from autologous physiological fluid
AU2010300611A8 (en) Hematopoietic stem cells for use in the treatment of a kidney injury
GEP201706716B (en) Optimised subcutaneous therapeutic agents
MX2014000567A (es) Tratamiento de lesion por radiacion utilizando celulas adherentes derivadas del amnios.
EA201790563A8 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
MX2015007402A (es) Fusion de hormona de crecimiento humano y albumina, formulacion y usos de los mismos.
EA201691328A1 (ru) Бета-шпилечные пептидомиметики в качестве селективных ингибиторов эластазы
WO2012177660A3 (en) Leukotoxin e/d as a new anti-inflammatory agent and microbicide
RU2014145351A (ru) КОМБИНАЦИЯ АНАЛОГОВ СОМАТОСТАТИНА С ИНГИБИТОРАМИ 11β-ГИДРОКСИЛАЗЫ
CN104548194A (zh) 一种医用高性能粘合剂
BR112016028561A2 (pt) composição, forma de dosagem, e, métodos para reduzir o risco para mortalidade em um indivíduo, o risco para uma doença ou condição em um indivíduo, triglicerídeos em um sangue de indivíduo, a frequência cardíaca em repouso de um indivíduo, o colesterol de lipoproteína de densidade não alta em um indivíduo, o colesterol total em um indivíduo, a apolipoproteína b em um sangue de indivíduo, pressão sanguínea sistólica em um indivíduo e a pressão sanguínea diastólica em um indivíduo, para prolongar a vida de um indivíduo, para tratar hipertrigliceridemia em um indivíduo e para aumentar um índice de ômega-3 em células vermelhas do sangue de um indivíduo.